Q-omics provides the consensus-scored DYM profile across patient tissues and cancer cell-line models. DYM expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DYM is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, DYM RNA expression shows 19,620 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, LIHC, and ACC as cancer lineages where DYM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DYM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DYM survival associations across molecular data types. DYM RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DYM RNA expression–survival associations across cancer types. High DYM expression shows unfavorable associations in BLCA, ACC and LIHC, but favorable associations in KIRC, COAD and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for DYM RNA expression.
This table summarizes DYM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for DYM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DYM shows lower tumor expression in BLCA, THCA and KICH and higher tumor expression in LIHC, CHOL and LUSC. The LIHC box plot shows higher DYM RNA expression in tumor versus normal tissue (log2 FC = +1.080, t-test p < 0.001).
This table shows molecular features associated with DYM in patient tissues and cancer cell lines. In patient samples, DYM shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DYM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
